Patients with Parkinson's disease (PD) often have cognitive deficits from the time of diagnosis. 4 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
32,580 Alzheimer's and dementia studies in plain English, each scored out of 100.
Patients with Parkinson's disease (PD) often have cognitive deficits from the time of diagnosis. 4 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Reductions in cholinergic function occur in Alzheimer disease (AD) and dementia with Lewy bodies and correlate with cognitive decline. 4 key findings →
Participants: 89 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We investigated consecutive patients with dementia. 4 key findings →
Participants: 536 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Our study reveals that PS in DLB is associated with specific deficits in attention and visuospatial/executive function, alongside more severe neuropsychiatric symptoms. 5 key findings →
Design: longitudinal study Participants: 35 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The objective of this study was to examine the quality of life in patients with Parkinson's disease (PD) in a community-based sample (n = 228 patients) using a Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) as a measure. 4 key findings →
Participants: 228 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Both patient groups performed equally poorly on tests of episodic and semantic memory with the exception of immediate and delayed story recall, which was worse in the AD group. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Cognitive impairment is common in Parkinson's disease (PD). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Cognitive impairment (CI) and dementia are frequent and debilitating features associated with Parkinson's disease (PD). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Gait abnormalities are associated with cognitive decline, and reduced gait speed and gait asymmetry are markers of cognitive decline and increased fall risk in patients with established DLB. 5 key findings →
Design: cross-sectional Participants: 63 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Similar to Alzheimer's disease (AD), dementia with Lewy bodies (DLB) is characterized by a profound degeneration of cortically-projecting cholinergic neurons of the basal forebrain (BF) and associated depletion of cortical cholinergic activity. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
About one fourth of Lewy body disease (LBD) patients show cortical beta-amyloid load, basically a hallmark of Alzheimer disease (AD). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Showa University Karasuyama Hospital, Tokyo, Japan. 4 key findings →
Participants: 106 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In patients with cognitive impairment due to diverse causes, the HTS might occur regardless of MCI versus dementia status and across different etiologies. 4 key findings →
Participants: 121 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Differences in regional cerebral blood flow (rCBF) between subjects with Alzheimer's disease (AD), dementia with Lewy bodies (DLB) and healthy volunteers were investigated using statistical parametric mapping (SPM99). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The Benson Complex Figure Test (BCFT) is a neuropsychological tool designed to assess visuospatial construction and visual memory with lower complexity than traditional tests. 4 key findings →
Design: cross-sectional Participants: 1,428 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Compared to controls, the AD/VaD patient group had a significantly higher WML volume (p < .001), reduced global CBF (p < .001), greater brain atrophy, and worse ADAS-Cog scores (p < .001). 5 key findings →
Design: cross-sectional Participants: 100 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Galantamine appears to be an effective and safe therapy for patients with DLB. 2 key findings →
Design: open-label trial Participants: 50 Evidence: low
Full summary, score breakdown and related studies → Original source
CogState and standard neuropsychological task scores were significantly lower for dementia participants than that of the nondementia groups (P < .05), with a single CogState test distinguishing control from MCI participants, but minimal differentiation existing between dementias using the CogState. 2 key findings →
Participants: 37 Evidence: low
Full summary, score breakdown and related studies → Original source
In established dementia, administration of the CogState tasks appears sensitive to cognitive impairment in dementia. 1 key finding →
Participants: 23 Evidence: low
Full summary, score breakdown and related studies → Original source
The idea that eye movements can reflect certain aspects of brain function and inform on the presence of neurodegeneration is not a new one. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The VRFCAT-SL appears to provide a useful measure of cognitive functional capacity that is not confounded by PD motor symptoms. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The Montreal Cognitive Assessment (MoCA) is a brief instrument developed for the screening of milder forms of cognitive impairment, having surpassed the well-known limitations of the MMSE. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Individual cognitive profiles of patients with Parkinson's disease dementia (PDD) are highly heterogeneous, suggesting possible biological subtypes. 1 key finding →
Participants: 50 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The DET framework has achieved superior performance on the classification task across all the evaluation metrics compared to the traditional machine learning based methods, as demonstrated in Table 1. 4 key findings →
Participants: 106 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
White matter hyperintensities (WMH) on MRI scans indicate lesions of the subcortical fiber system. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 32,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 32,580 records, built mostly from automated pulls of Europe PMC (66.9% of the library) and OpenAlex (15.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,045 records (3.2% of the library) are not peer-reviewed — 966 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events
Last updated